PureTech Continues $50M Share Buyback Program, Second Tranche Underway
Ticker: PTCHF · Form: 6-K · Filed: Jan 4, 2024 · CIK: 1782999
| Field | Detail |
|---|---|
| Company | Puretech Health PLC (PTCHF) |
| Form Type | 6-K |
| Filed Date | Jan 4, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $50 million, $25 million |
| Sentiment | bullish |
Complexity: simple
Sentiment: bullish
Topics: share-repurchase, buyback, corporate-action
TL;DR
**PureTech is buying back its own stock, which could make your shares more valuable.**
AI Summary
PureTech Health plc announced on January 4, 2024, that it is continuing its $50 million share repurchase program, initially announced on May 9, 2022. The program is split into two $25 million tranches, with the first completed on October 26, 2022. The second tranche, managed by Jefferies International Limited, involves buying back Ordinary Shares on the London Stock Exchange. This matters to investors because share repurchases can reduce the number of outstanding shares, potentially increasing earnings per share and signaling management's confidence in the company's valuation.
Why It Matters
Share repurchases can boost shareholder value by reducing the number of outstanding shares, which can increase earnings per share and signal that management believes the stock is undervalued.
Risk Assessment
Risk Level: low — Share repurchase programs are generally seen as a positive or neutral event for investors, indicating financial health and a commitment to shareholder returns.
Analyst Insight
A smart investor would monitor the progress of the second tranche of the share repurchase program, as a reduced share count could positively impact per-share metrics and potentially the stock price.
Key Numbers
- $50 million — Total Share Repurchase Program Value (The total amount PureTech Health plc plans to spend buying back its shares.)
- $25 million — Value per Tranche (The amount allocated to each of the two equal parts of the share repurchase program.)
- 20231231 — Conformed Period of Report (The period this 6-K filing covers, indicating the activity up to the end of December 2023.)
Key Players & Entities
- PureTech Health plc (company) — the registrant executing the share repurchase program
- $50 million (dollar_amount) — total value of the share repurchase program
- May 9, 2022 (date) — date the share repurchase program was initially announced
- October 26, 2022 (date) — date the first tranche of the share repurchase program was completed
- Jefferies International Limited (company) — the firm executing the share repurchases for PureTech
- $25 million (dollar_amount) — value of each tranche of the share repurchase program
Forward-Looking Statements
- PureTech's share price may see upward pressure due to reduced share count. (PureTech Health plc) — medium confidence, target: Q1 2024
- Earnings per share (EPS) for PureTech could improve as a result of the buyback. (PureTech Health plc) — medium confidence, target: Next Earnings Report
FAQ
What is the total value of PureTech Health plc's share repurchase program?
The total value of PureTech Health plc's share repurchase program is $50 million, as announced on May 9, 2022.
How many tranches is the share repurchase program divided into, and what is the value of each?
The program is divided into two equal tranches, with each tranche having an aggregate consideration of no greater than $25 million.
When was the first tranche of the share repurchase program completed?
The first tranche of the share repurchase program was completed on October 26, 2022.
Which firm is PureTech Health plc using to execute the share repurchases for the second tranche?
PureTech Health plc has entered into an irrevocable non-discretionary instruction with Jefferies International Limited to execute the purchases for the second tranche.
Where are the Ordinary Shares for the second tranche of the program being purchased?
Any purchase of Ordinary Shares under the second tranche of the Program are carried out on the London Stock Exchange and any other UK recognized investment exchange which may be agreed.
Filing Stats: 751 words · 3 min read · ~3 pages · Grade level 7.5 · Accepted 2024-01-04 16:30:55
Key Financial Figures
- $50 million — ompany) announced the commencement of a $50 million share repurchase program (the Program)
- $25 million — (excluding expenses) of no greater than $25 million and the simultaneous on-sale of such Or
Filing Documents
- d817352d6k.htm (6-K) — 25KB
- 0001193125-24-002462.txt ( ) — 26KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. PURETECH HEALTH PLC Date: January 4, 2024 By: /s/ Daphne Zohar Name: Daphne Zohar Title: Chief Executive Officer